BH3 Stock Overview A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
PTC Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for PTC Therapeutics Historical stock prices Current Share Price US$43.00 52 Week High US$49.60 52 Week Low US$22.00 Beta 0.63 1 Month Change 1.42% 3 Month Change 29.52% 1 Year Change 69.29% 3 Year Change 21.47% 5 Year Change 0.94% Change since IPO 221.54%
Recent News & Updates
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia Dec 19
An undisclosed buyer entered into an agreement to acquire Rare Pediatric Disease Priority Review Voucher of PTC Therapeutics, Inc. from PTC Therapeutics, Inc. (NasdaqGS:PTCT) for $150 million. Nov 29
PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients Nov 27
PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy Nov 14
New minor risk - Profitability Nov 11
New minor risk - Shareholder dilution Nov 10 See more updates
PTC Therapeutics, Inc. Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia Dec 19
An undisclosed buyer entered into an agreement to acquire Rare Pediatric Disease Priority Review Voucher of PTC Therapeutics, Inc. from PTC Therapeutics, Inc. (NasdaqGS:PTCT) for $150 million. Nov 29
PTC Therapeutics, Inc. Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients Nov 27
PTC Therapeutics, Inc. Announces FDA Approval of AADC Deficiency Gene Therapy Nov 14
New minor risk - Profitability Nov 11
New minor risk - Shareholder dilution Nov 10
Third quarter 2024 earnings released: US$1.39 loss per share (vs US$1.76 loss in 3Q 2023) Nov 08
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024 Nov 08
PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission Nov 02
PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination Oct 18
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results Oct 15
PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program Oct 08
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients Oct 02
New minor risk - Profitability Aug 09
Second quarter 2024 earnings released: US$1.29 loss per share (vs US$2.66 loss in 2Q 2023) Aug 09
PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda Jul 30
PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients Jun 20
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza May 15
PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Apr 27
First quarter 2024 earnings released: US$1.20 loss per share (vs US$1.89 loss in 1Q 2023) Apr 26
PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024 Apr 12
New major risk - Share price stability Mar 29
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA Mar 28
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency Mar 20
Full year 2023 earnings released: US$8.37 loss per share (vs US$7.79 loss in FY 2022) Mar 01
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 Mar 01
PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure Jan 26
CEO & Director recently sold €250k worth of stock Jan 10
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024 Jan 08
PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities Dec 06
PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023 Oct 28
New major risk - Financial position Oct 27
PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 25
New major risk - Financial position Sep 19
New minor risk - Profitability Aug 07
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: US$2.66 loss per share (vs US$2.13 loss in 2Q 2022) Aug 04
PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures Jun 30
Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients Jun 22
PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization May 25
PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023 May 24 PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria May 18
First quarter 2023 earnings released: US$1.89 loss per share (vs US$1.78 loss in 1Q 2022) Apr 30
CEO, COO & Director recently sold €57k worth of stock Apr 21
Forecast to breakeven in 2025 Feb 23
Full year 2022 earnings released: US$7.79 loss per share (vs US$7.44 loss in FY 2021) Feb 22
Co-Founder recently sold €110k worth of stock Feb 05
Co-Founder recently sold €80k worth of stock Jan 13
PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023 Jan 10
PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors Dec 07
PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil Dec 02
Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™ Nov 18
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.89 loss in 3Q 2021) Oct 28 PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.
PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 Oct 19
Insider recently sold €116k worth of stock Aug 13
PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates Aug 06
Second quarter 2022 earnings released: US$2.13 loss per share (vs US$1.68 loss in 2Q 2021) Aug 05 PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022
PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency Jul 21
PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors Jun 10
PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study Jun 04
PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old May 31
PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency May 21
First quarter 2022 earnings released: US$1.78 loss per share (vs US$1.83 loss in 1Q 2021) May 05
PTC Therapeutics, Inc. Provides Earnings Guidance for 2022 May 05
Insufficient new directors Apr 27
PTC Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 20
PTC Therapeutics, Inc. Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program Apr 15
PTC Therapeutics, Inc. Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease Mar 31
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
PTC Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2022 Feb 24
Co-Founder recently sold €80k worth of stock Feb 07
PTC Therapeutics, Inc. Announces FDA Grants Evrysdi® Priority Review Based on Results from Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy Jan 25
Co-Founder recently sold €73k worth of stock Jan 13
PTC Therapeutics, Inc. Reports Earnings Guidance for the Year 2021 and 2022 Jan 12
Insufficient new directors Jan 02
Forecast to breakeven in 2024 Jan 01
Oral Splicing Modifiers Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform Dec 21
Third quarter 2021 earnings released: US$1.89 loss per share (vs US$1.03 loss in 3Q 2020) Oct 29
PTC Therapeutics, Inc. Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome Aug 24
Insider recently sold €56k worth of stock Aug 18
Second quarter 2021 earnings released: US$1.68 loss per share (vs US$2.79 loss in 2Q 2020) Jul 31
PTC Therapeutics, Inc. Announces Results of Evidence Confirming Emflaza®'s Benefit over Prednisone Jun 25
PTC Therapeutics, Inc. Announces Evrysdi™ Approval in Japan for the Treatment of Spinal Muscular Atrophy Jun 24
Ptc Therapeutics, Inc. Announces Pre-Symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in Rainbowfish Jun 11
PTC Therapeutics, Inc. Announces Data from the First Study on the Impact of Caring for Child with the Ultra-Rare Genetic Disorder, Aromatic L-Amino Acid Decarboxylase Deficiency May 18
First quarter 2021 earnings released: US$1.83 loss per share (vs US$1.81 loss in 1Q 2020) May 06
PTC Therapeutics, Inc. Reaffirms Earnings Guidance for Full Year 2021 May 05 Shareholder Returns BH3 DE Biotechs DE Market 7D 0% 3.1% 0.5% 1Y 69.3% -13.8% 7.2%
See full shareholder returns
Return vs Market: BH3 exceeded the German Market which returned 7.2% over the past year.
Price Volatility Is BH3's price volatile compared to industry and market? BH3 volatility BH3 Average Weekly Movement 9.9% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BH3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BH3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
Show more PTC Therapeutics, Inc. Fundamentals Summary How do PTC Therapeutics's earnings and revenue compare to its market cap? BH3 fundamental statistics Market cap €3.35b Earnings (TTM ) -€434.67m Revenue (TTM ) €863.83m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BH3 income statement (TTM ) Revenue US$900.66m Cost of Revenue US$601.30m Gross Profit US$299.37m Other Expenses US$752.57m Earnings -US$453.20m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.88 Gross Margin 33.24% Net Profit Margin -50.32% Debt/Equity Ratio -224.5%
How did BH3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/29 11:38 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources PTC Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Huidong Wang Barclays Geoffrey Meacham Barclays
Show 24 more analysts 
